Display options
Cite
Sofi-Mahmudi A, Masinaei M, Shamsoddin E, et al. Global, regional, and national burden and quality of care index (QCI) of lip and oral cavity cancer: a systematic analysis of the Global Burden of Disease Study 1990-2017. BMC Oral Health. 2021;21(1):558doi: 10.1186/s12903-021-01918-0.
Sofi-Mahmudi, A., Masinaei, M., Shamsoddin, E., Tovani-Palone, M. R., Heydari, M. H., Shoaee, S., Ghasemi, E., Azadnajafabad, S., Roshani, S., Rezaei, N., Rashidi, M. M., Kalantar Mehrjardi, R., Hajebi, A. A., Larijani, B., & Farzadfar, F. (2021). Global, regional, and national burden and quality of care index (QCI) of lip and oral cavity cancer: a systematic analysis of the Global Burden of Disease Study 1990-2017. BMC oral health, 21(1), 558. https://doi.org/10.1186/s12903-021-01918-0
Sofi-Mahmudi, Ahmad, et al. "Global, regional, and national burden and quality of care index (QCI) of lip and oral cavity cancer: a systematic analysis of the Global Burden of Disease Study 1990-2017." BMC oral health vol. 21,1 (2021): 558. doi: https://doi.org/10.1186/s12903-021-01918-0
Sofi-Mahmudi A, Masinaei M, Shamsoddin E, Tovani-Palone MR, Heydari MH, Shoaee S, Ghasemi E, Azadnajafabad S, Roshani S, Rezaei N, Rashidi MM, Kalantar Mehrjardi R, Hajebi AA, Larijani B, Farzadfar F. Global, regional, and national burden and quality of care index (QCI) of lip and oral cavity cancer: a systematic analysis of the Global Burden of Disease Study 1990-2017. BMC Oral Health. 2021 Nov 02;21(1):558. doi: 10.1186/s12903-021-01918-0. PMID: 34724951; PMCID: PMC8561915.
Copy Download .nbib Format: NLM
Share it on

BMC Oral Health. 2021 Nov 02;21(1):558. doi: 10.1186/s12903-021-01918-0.

Global, regional, and national burden and quality of care index (QCI) of lip and oral cavity cancer: a systematic analysis of the Global Burden of Disease Study 1990-2017.

BMC oral health

Ahmad Sofi-Mahmudi, Masoud Masinaei, Erfan Shamsoddin, Marcos Roberto Tovani-Palone, Mohammad-Hossein Heydari, Shervan Shoaee, Erfan Ghasemi, Sina Azadnajafabad, Shahin Roshani, Negar Rezaei, Mohammad-Mahdi Rashidi, Reyhaneh Kalantar Mehrjardi, Amir Ali Hajebi, Bagher Larijani, Farshad Farzadfar

Affiliations

  1. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  2. Cochrane Iran Associate Centre, National Institute for Medical Research Development (NIMAD), Tehran, Iran.
  3. Department of Epidemiology and Biostatistics, Tehran University of Medical Sciences, Tehran, Iran.
  4. Ribeirão Preto Medical School, University of São Paulo, São Paulo, 14049-900, Brazil.
  5. School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  6. Elderly Health Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  7. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  8. Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. [email protected].
  9. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran. [email protected].

PMID: 34724951 PMCID: PMC8561915 DOI: 10.1186/s12903-021-01918-0

Abstract

BACKGROUND: To measure the quality of care for lip and oral cavity cancer worldwide using the data from the Global Burden of Disease (GBD) Study 2017.

METHODS: After devising four main indices of quality of care for lip and oral cavity cancer using GBD 2017 study's measures, including prevalence, incidence, years of life lost, years lived with disability, and disability-adjusted life years, we utilised principal component analysis (PCA) to determine a component that bears the most proportion of info among the others. This component of the PCA was considered as the Quality-of-Care Index (QCI) for lip and oral cavity cancer. The QCI score was then reported in both men and women worldwide and different countries based on the socio-demographic index (SDI) and World Bank classifications.

RESULTS: Between 1990 and 2017, care quality continuously increased globally (from 53.7 to 59.6). In 1990, QCI was higher for men (53.5 for men compared with 50.8 for women), and in 2017 QCI increased for both men and women, albeit a slightly higher rise for women (57.2 for men compared with 59.9 for women). During the same period, age-standardised QCI for lip and oral cavity cancer increased in all regions (classified by SDI and World Bank). Globally, the highest QCI scores were observed in the elderly age group, whereas the least were in the adult age group. Five countries with the least amount of QCIs were all African. In contrast, North American countries, West European countries and Australia had the highest indices.

CONCLUSION: The quality of care for lip and oral cavity cancer showed a rise from 1990 to 2017, a promising outcome that supports patient-oriented and preventive treatment policies previously advised in the literature. However, not all countries enjoyed such an increase in the QCI to the same extent. This alarming finding could imply a necessary need for better access to high-quality treatments for lip and oral cavity cancer, especially in central African countries and Afghanistan. More policies with a preventive approach and paying more heed to the early diagnosis, broad insurance coverage, and effective screening programs are recommended worldwide. More focus should also be given to the adulthood age group as they had the least QCI scores globally.

© 2021. The Author(s).

Keywords: DALY; Global burden of disease; Lip and oral cavity cancer; Quality of care

References

  1. PLoS One. 2018 Oct 18;13(10):e0205731 - PubMed
  2. J Cancer Res Ther. 2007 Apr-Jun;3(2):127-30 - PubMed
  3. J Cancer Res Ther. 2016 Apr-Jun;12(2):458-63 - PubMed
  4. Cancers (Basel). 2016 Sep 02;8(9): - PubMed
  5. Oral Oncol. 2017 Jul;70:23-28 - PubMed
  6. Tumour Biol. 2017 Oct;39(10):1010428317725923 - PubMed
  7. Cancer Commun (Lond). 2020 Mar;40(2-3):81-92 - PubMed
  8. Lancet. 2018 Nov 10;392(10159):1736-1788 - PubMed
  9. Am J Surg. 2011 May;201(5):645-9 - PubMed
  10. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD004150 - PubMed
  11. Asian Pac J Cancer Prev. 2016;17(8):3687-96 - PubMed
  12. JAMA Oncol. 2015 Jul;1(4):505-27 - PubMed
  13. Lancet. 2005 Jun 4-10;365(9475):1927-33 - PubMed
  14. Health Technol Assess. 2006 Apr;10(14):1-144, iii-iv - PubMed
  15. Oral Oncol. 2014 Oct;50(10):976-82 - PubMed
  16. Lancet Oncol. 2018 Oct;19(10):1289-1306 - PubMed
  17. Br Dent J. 2009 Nov 28;207(10):471-5 - PubMed
  18. MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):433-438 - PubMed
  19. Epidemiol Health. 2017 Mar 9;39:e2017009 - PubMed
  20. Soc Sci Med. 1996 Sep;43(5):707-20 - PubMed
  21. Br J Gen Pract. 2019 Feb;69(679):e112-e126 - PubMed
  22. CA Cancer J Clin. 2020 Jan;70(1):7-30 - PubMed
  23. Exp Hematol Oncol. 2021 Feb 8;10(1):11 - PubMed
  24. J Support Oncol. 2010 Jan-Feb;8(1):4-12 - PubMed
  25. Oral Oncol. 2004 Mar;40(3):304-13 - PubMed
  26. Evid Based Dent. 2009;10(1):4-5 - PubMed
  27. Lancet. 2018 Nov 10;392(10159):1789-1858 - PubMed
  28. Cancer Med. 2021 Apr;10(7):2496-2508 - PubMed
  29. Crit Rev Oncol Hematol. 2017 Feb;110:81-93 - PubMed
  30. Semin Oncol. 2017 Jun;44(3):178-186 - PubMed
  31. Lancet. 2018 Jun 2;391(10136):2236-2271 - PubMed
  32. J Cancer Educ. 2010 Sep;25(3):279-81 - PubMed
  33. J Clin Oncol. 2013 Mar 1;31(7):910-5 - PubMed
  34. Lancet Public Health. 2019 Jan;4(1):e49-e73 - PubMed
  35. PLoS One. 2021 Feb 22;16(2):e0247120 - PubMed
  36. Nagoya J Med Sci. 2019 Aug;81(3):407-414 - PubMed
  37. CA Cancer J Clin. 2017 Jan;67(1):51-64 - PubMed
  38. Br J Cancer. 2009 May 19;100(10):1566-74 - PubMed
  39. Int J Clin Oncol. 2008 Apr;13(2):102-11 - PubMed
  40. Oral Oncol. 2009 Apr-May;45(4-5):454-60 - PubMed
  41. Int J Nanomedicine. 2014 Aug 08;9:3719-35 - PubMed
  42. Oncotarget. 2018 Feb 26;9(21):15591-15605 - PubMed
  43. JAMA Oncol. 2017 Apr 1;3(4):524-548 - PubMed
  44. Oncologist. 2010;15(9):994-1001 - PubMed
  45. Urol Oncol. 2018 Oct;36(10):469.e1-469.e11 - PubMed
  46. J Womens Health (Larchmt). 2012 Feb;21(2):140-5 - PubMed
  47. Br Dent J. 2018 Nov 9;225(9):815-819 - PubMed
  48. Pharmaceutics. 2019 Jun 30;11(7): - PubMed
  49. Pancreatology. 2021 Sep 10;: - PubMed
  50. Am Health Drug Benefits. 2013 Jul;6(6):321-9 - PubMed

Publication Types